← All diseases

Blood and immune system diseases

Glanzmann thrombasthenia

An inherited bleeding disease in which blood platelets cannot come together to form a clot. Easy bruising and prolonged bleeding are seen from birth.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

Orphanet has a guideline for emergency doctors for this disease (language: French, Italian). See on Orphanet

Prepare an emergency card

This page is translated from the Turkish original.

This disease is followed through the “Blood and immune system diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

Platelets are tiny blood cells that stick to each other to stop bleeding. To do this, they have a special receptor protein on their surface. In this disease, that protein is missing or faulty. The platelet count is usually normal, but the cells cannot clump together. This is why bleeding lasts a long time.

Which symptoms can occur?

How severe the bleeding is varies greatly from person to person, even within the same family. Spontaneous bleeding tends to decrease with age.

  • Easy bruising
  • Frequent nosebleeds
  • Bleeding gums
  • Red or purple spots on the skin
  • Prolonged bleeding after a wound, surgery or dental treatment
  • Heavy and long menstrual periods
  • Bleeding in the stomach and gut (in about a quarter)
  • Bleeding inside the head or into the joints (rare)

How is it diagnosed?

The platelet count is usually normal, but the bleeding time is long. Platelet clumping tests give abnormal results. The definite diagnosis is made with a special blood test that shows the receptor protein is missing. A genetic test can find the gene change that causes the disease.

Treatment and care

Platelet transfusions are given when there is bleeding or before surgery. Medicines that stop a clot from breaking down too early are also used. If platelet transfusions do not work, an approved clotting factor treatment can be given. Hormone treatment helps with heavy menstrual bleeding. Regular dental care is important. Some people with severe disease have been cured with a stem cell transplant. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

The disease is passed on through recessive inheritance. The mother and father are carriers but usually have no symptoms. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Girls and boys are affected equally. Recessive diseases may be more common in marriages between relatives. In genetic counselling, carrier testing and prenatal testing can be discussed.

Source: MedlinePlus Genetics: Glanzmann thrombasthenia · NORD: Glanzmann Thrombasthenia

Key facts

How is it inherited?
Autosomal recessive
When does it usually start?
Infancy, Newborn period
Gene(s) involved
ITGA2B, ITGB3

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about Glanzmann

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 3 active interventional studies for this disease. 2 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Blood and immune system diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:849

No separate ICD-11 code; WHO classifies this disease under: 3B62.0Y

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.